Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.

Therapeutic Effects of Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01256125

Enrollment

Registered

2010-12-08

Start date

2010-10-31

Completion date

Unknown

Last updated

2010-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allogene MSCs Transplantation, Chronic Liver Diseases Patients, Peripheral Vein

Keywords

allogene MSCs, transplantation, chronic liver diseases, peripheral vein

Brief summary

Allogene MSCs transplantation will be performed in patients with chronic liver diseases through peripheral vein and therapeutic effects including short-term effects and long-term follow-up will be compared and investigated.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease. 2. age: 15-65 years old.

Exclusion criteria

1. pregnant women and women in lactation. 2. other systems and organs disfunction 3. space-occupying lesion were found in liver. 4. concurrent infection with HIV and other immunodeficiency diseases. 5. DIC and active bleeding were confirmed.

Design outcomes

Primary

Measure	Time frame
Short-term therapeutic effects at 1-8 weeks after Allogene MSCs transplantation through peripheral vein.	1-8 weeks after transplantation

Secondary

Measure	Time frame
Long-term follow-up of Allogene MSCs transplantation through peripheral vein.	3-60 months

Countries

China

Outcome results